Page 15 - டாகேடா மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Emerging Biopharma: Your Next 2 Geographic Markets To Tackle After The US By Paul Brennan, CEO, NervGen Pharma Corp. While the majority of the world’s drug development and innovation are underwritten by the United States, emerging drug developers should not overlook two major regions of the world that represent volume, profit, ingenuity, and growth. U.S. pharma R&D has grown from $2 billion in 1980 to over $64.3 billion by 2019 according to PhRMA, but drug and biologics developers should not overlook the key regions of Europe and Japan when building a growth plan. US Pricing Pays For Global Innovation The pricing and reimbursement system in the U.S. pays for innovation and it results in pharmaceutical piggybacking in the rest of world. If it works in the U.S., you know it can work anywhere. Unlike other countries, the U.S. does not authorize drug price regulation to control pharmaceutical spending, so as not to depress the flow of capital to support the development of new pharm

United statesUnited kingdomPaul brennanBrickell biotech incSchaeffer centerKaken pharmaceutical co ltdNervgen pharma corpCohbar incUniversity of liverpoolMerck kgaMerck kgaaMckinsey companyHealth policy economicNervgen pharmaHealth policyTakeda pharmaceutical